Analysis of hospitalization for malignant neoplasm of the bladder in Brazil between the period 2011 to august 2022
Keywords:Neoplasm; Bladder; Hospitalization.
The malignant neoplasm of the bladder is a cancer that settles in the cells that cover the internal walls of the bladder, an organ of extreme importance in the storage of urine. About 90% of patients affected by the pathology only receive the diagnosis after 55 years of age, the age group in which this tumor is more present. To analyze the number and variables of hospitalization rates for malignant bladder cancer in Brazil. This is a quantitative and retrospective study with data collection from the Department of Informatics of the Unified Health System - DATASUS. The research was carried out using information from vital statistics in the Hospital Morbidity Group of the SUS (SIH/SUS). Data available from the CID 10 for both sexes, age groups and region with the highest incidence were analyzed. During the analyzed period, 181,687 cases of hospitalization for malignant neoplasm of the bladder were found. Regarding gender, 70.71% of the cases are male and 29.29% are female. Of the age groups, hospitalizations are more prevalent between 60 and 69 years of age, with 31.71% of the total cases of hospitalization for malignant neoplasm of the bladder, with 56.76% of the Southeast region having the highest cases of notifications. Bladder tumors occur two to three times more often in men than in women, which is consistent with the high rate of hospitalizations of the male population in Brazil due to bladder cancer. It is known that the peak incidence of the disease, as it is caused by failures in the genetic material, is linked to older ages, especially after 55 years of age. This factor elucidates the prevalence of hospitalizations among the elderly. The southeastern region of Brazil, being the area with the largest absolute population, and, therefore, having a greater number of elderly people, naturally presents more than half of the cases of hospitalization in the country. It appears, therefore, that the number of hospitalizations for malignant neoplasm of the bladder is higher in males, especially in the age group between 50 and 59 years, with a marked emphasis on the southeastern region of the country.
Bellmunt, J., Choueiri, T. K., Fougeray, R., Schutz, F. A. B., Salhi, Y., Winquist, E., et al (2010). Prognostic Factors in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract Experiencing Treatment Failure With Platinum-Containing Regimens. J Clin Oncol. 2010 Apr;28(11):1850–5. 26.
Brasil Ministério da Saúde (2004). TNM: classificação de tumores malignos. (6a ed.):INCA;2004
Cao, Y., He, Y., Chen, H., He, S., Gu, Y., Wang, X., et al (2018). Phase I study of gemcitabine-cisplatin versus pemetrexed cisplatin for patients with advanced or metastatic bladder cancer. J BUON. 2018;23(2):475–81. 24.
Crist, M., & Balar. A. (2017) Atezolizumab in invasive and metastatic urothelial carcinoma. Expert Rev Clin Pharmacol. 2017 Dec;10(12):1295–301.
Freeman, J. A., Esrig, D., Stein, J. P., Simoneau, A. R., Skinner, E. C., Chen, S. C., et al.(1995) Radical cystectomy for high risk patients with superficial bladder cancer in the era of orthotopic urinary reconstruction. Cancer 1995;76:833-9
Godwin, J. L., Hoffman-Censits, J., & Plimack, E. (2018) Recent developments in the treatment of advanced bladder cancer. Urol Oncol Semin Orig Investig. 2018 Mar;36(3):109–14. 25.
Grimm, M. O., Steinhoff, C., Simon, X., Spiegelhalder, P., Ackermann, R., & Vogeli, T. A. (2003). Effectof routine repeat transurethral resection for superficial bladder cancer: a long-term observational study. J Urol 2003
Grossman, H. B. (1998).New methods for detection of bladder cancer. Semin Urol Oncol1998;16:17-22.
Hain, S. F., & Maisey, M. N. (2003).Positron emission tomography for urological tumours. BJU Int 2003;92:159-64
Herranz-Amo, F., Diez-Cordero, J. M., VerduTartajo,. F, Bueno-Chomon, G., LealHernandez, F., & Bielsa-Carrillo, A (1999).Need for intravenous urography in patients with primary transitional carcinoma of the bladder? Eur Urol 1999;36:221-4
Jakse, G., Algaba, F., Malmstrom, P. U., & Oosterlinck, W. (2004). A second-look TUR in T1transitional cell carcinoma: why? Eur Urol 2004;45:539-46
Khadra, M. H., Pickard, R. S., Charlton, M., Powell, P. H., & Neal, D. E. (2000). A prospective analysis of1,930 patients with hematuria to evaluate current diagnostic practice. J Urol 2000;163:524-7
Kriegmair, M., Zaak, D., Knuechel, R., Baumgartner, R., & Hofstetter, A. (1999). Photodynamic cystoscopy for detection of bladder tumors. Semin Laparosc Surg 1999; 6:100-3
Messing, E. M., & Vaillancourt, A. (1990). Hematuria screening for bladder cancer. J Occup Med1990;32:838-45.
Nagele, U., Anastasiadis, A. G., Stenzl, A., & Kuczyk, M. (2012).Radical cystectomy with orthotopic neobladder for invasive bladder cancer: a critical analysis of long-term oncological, functional, and quality of life results. World J Urol. 2012 Dec;30(6):725–32. 23.
Sella, A., Dexeus, F. H., Chong, C., Ro,. J Y., & Logothetis, C. J.(1989).Radiation therapy-associated invasive bladder tumors. Urology 1989;33:185-8
Shabsigh, A., Korets, R., Vora, K. C., Brooks, C. M., Cronin, A. M., Savage, C., et al (2009). Defining Early Morbidity of Radical Cystectomy for Patients with Bladder Cancer Using a Standardized Reporting Methodology. Eur Urol. 2009 Jan;55(1):164–76. 22.
Sylvester, R. J., Oosterlinck, W., & van der Meijden, A. P.(2004).A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a metaanalysis of published results of randomized clinical trials. J Urol 2004;171(6 Pt 1):2186-90
Thomas, F., Noon, A. P., Rubin, N., Goepel, J. R., & Catto, J. W. F. (2013). Comparative Outcomes of Primary, Recurrent, and Progressive High-risk Non– muscle-invasive Bladder Cancer. Eur Urol. 2013 Jan;63(1):145–54. 21.
Witjes, J. A., Compérat, E., Cowan, N. C., De Santis, M., Gakis, G., & Lebrét, T., et al (2016). EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. 2016
How to Cite
Copyright (c) 2023 Joaquim Fernandes de Morais Neto; Luis Miguel Carvalho Mendes; Marcio Adriano Gomes Ferreira Filho; Lucas Carvalho Mendes; Lucas Arruda Lino; Anderson Pereira da Silva; Lucas Félix Felicio Matos ; João Pedro Garcia ; João Pedro Brito Madeira; Ronaldo Luís Oliveira Delgado
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.